• Top 20 Pharma – 26.2%
• Small/Mid-Tier Pharma – 18.6%
• Generic Pharma – 9.5%
• Specialty Pharma – 9.0%
• Virtual Pharma – 8.6%
• Emerging Biopharma – 7.2%
• Top 10 Biopharma – 6.8%
• Other – 14.0%

Holding the Fort?

Last year, 16% of total respondents believed that they’d spend the same or less on outsourcing spending in the coming year; this year, that number ballooned to 62%. Anticipating that we’d see reduced outsourcing spending in the recession, we changed the “less than last year” response to “1-5% less,” “6-10% less” and “10+% less.” Sadly, the 10+% less outsourcing spend group clocked in at 23% of total responses.

The no change in spending class grew from 6% to 25% in that span, but the number of respondents who said their spending would shrink rose from 10% to 37%. Last year, 23% of respondents reported they’d increase outsourcing spending by 10% or more; that number dropped to 16% this time around. A few years from now, we’ll look back on this and laugh. Trust me.

PS: Thanks to all of you who took the time to respond to this year’s Outsourcing Survey. The winner of our 16gb iPod Touch drawing is Pinar Cicalese of GlaxoSmithKline! Congratulations!